Abstract
Globally, the cancer associated deaths are generally attributed to the spread of cancerous cells or their features to the nearby or distant secondary organs by a process known as metastasis. Among other factors, the metastatic dissemination of cancer cells is attributed to the reactivation of an evolutionary conserved developmental program known as epithelial to mesenchymal transition (EMT). During EMT, fully differentiated epithelial cells undergo a series of dramatic changes in their morphology, along with loss of cell to cell contact and matrix remodeling into less differentiated and invasive mesenchymal cells. Many studies provide evidence for the existence of EMT like states in prostate cancer (PCa) and suggest its possible involvement in PCa progression and metastasis. At the same time, the lack of conclusive evidence regarding the presence of full EMT in human PCa samples has somewhat dampened the interest in the field. However, ongoing EMT research provides new perspectives and unveils the enormous potential of this field in tailoring new therapeutic regimens for PCa management. This review summarizes the role of many transcription factors and other molecules that drive EMT during prostate tumorigenesis
Keywords: Epithelial mesenchymal transition, prostate cancer, transcription factors, endoplasmic reticulum, stress, signaling, Y Box Protein-1.
Current Pharmaceutical Design
Title:Role of Epithelial Mesenchymal Transition in Prostate Tumorigenesis
Volume: 21 Issue: 10
Author(s): Mohammad Imran Khan, Abid Hamid, Vaqar Mustafa Adhami, Rahul K Lall and Hasan Mukhtar
Affiliation:
Keywords: Epithelial mesenchymal transition, prostate cancer, transcription factors, endoplasmic reticulum, stress, signaling, Y Box Protein-1.
Abstract: Globally, the cancer associated deaths are generally attributed to the spread of cancerous cells or their features to the nearby or distant secondary organs by a process known as metastasis. Among other factors, the metastatic dissemination of cancer cells is attributed to the reactivation of an evolutionary conserved developmental program known as epithelial to mesenchymal transition (EMT). During EMT, fully differentiated epithelial cells undergo a series of dramatic changes in their morphology, along with loss of cell to cell contact and matrix remodeling into less differentiated and invasive mesenchymal cells. Many studies provide evidence for the existence of EMT like states in prostate cancer (PCa) and suggest its possible involvement in PCa progression and metastasis. At the same time, the lack of conclusive evidence regarding the presence of full EMT in human PCa samples has somewhat dampened the interest in the field. However, ongoing EMT research provides new perspectives and unveils the enormous potential of this field in tailoring new therapeutic regimens for PCa management. This review summarizes the role of many transcription factors and other molecules that drive EMT during prostate tumorigenesis
Export Options
About this article
Cite this article as:
Khan Imran Mohammad, Hamid Abid, Adhami Mustafa Vaqar, Lall K Rahul and Mukhtar Hasan, Role of Epithelial Mesenchymal Transition in Prostate Tumorigenesis, Current Pharmaceutical Design 2015; 21 (10) . https://dx.doi.org/10.2174/1381612821666141211120326
DOI https://dx.doi.org/10.2174/1381612821666141211120326 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Validated HPLC-PDA Method for the Analysis of Ursolic Acid Content in Poly(lactic acid) Nanoparticles
Current Chromatography Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors
Mini-Reviews in Medicinal Chemistry MicroRNA and Exosome in Retinal-related Diseases: Their Roles in the Pathogenesis and Diagnosis
Combinatorial Chemistry & High Throughput Screening Update of QSAR & Docking & Alignment Studies of the DNA Polymerase Inhibitors
Current Bioinformatics Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design Structure Prediction of Neuroendocrine Convertase -2: A Potential Target in Various Cancers
Protein & Peptide Letters Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Design, Synthesis, and Evaluation of Genistein Analogues as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Endothelial Dysfunction Induced by Cadmium and Mercury and its Relationship to Hypertension
Current Hypertension Reviews CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers
Current Topics in Medicinal Chemistry Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry Central G-Protein Coupled Receptors (GPCR)s as Molecular Targets for the Treatment of Obesity: Assets, Liabilities and Development Status
Current Drug Targets - CNS & Neurological Disorders Editorial: Big Data and New Drug Discovery: Tackling “Big Data” for Virtual Screening of Large Compound Databases
Current Computer-Aided Drug Design Exploration of Metastasis-related Proteins as Biomarkers and Therapeutic Targets in the Treatment of Head and Neck Cancer
Current Cancer Drug Targets Molecule of the Month
Current Topics in Medicinal Chemistry The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry